Ginkgo Bioworks (DNA)

Ginkgo’s main operating activity is cell engineering. Through this segment, the company works with partners that want to develop organisms, enzymes, pathways, or biological products but may not have the in-house infrastructure to run large-scale biological research and development. Its platform combines foundry-style automation, organism engineering expertise, and accumulated biological “codebase” data to support projects from early design through iterative testing.

The company also operates a biosecurity business that focuses on detecting and monitoring biological threats. This work includes services for public-sector and commercial customers that need surveillance, testing, analytics, and response capabilities for pathogens and other biological risks. The biosecurity segment reflects Ginkgo’s broader view that the same technical capabilities used to engineer biology can also help society identify and mitigate biological hazards.

Ginkgo is distinctive because it is not built around a single drug, crop trait, or chemical product. Instead, it positions itself as an enabling platform for many industries that want to use biology as a manufacturing or discovery tool. Investors typically assess the company by its ability to convert partnerships and programs into durable revenue, manage research costs, and demonstrate that its platform can scale across diverse end markets.